James C. Yang, M.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10 CRC, Room 3-5952
- Bethesda, MD 20892
Dr. Yang is involved in the clinical and scientific study of T-cell adoptive therapy and other immunotherapies to treat melanoma and other cancers. He is particularly interested in expanding these modalities to other cancers such as renal, lung and thyroid cancer and is initiating these clinical protocols. His laboratory efforts have concentrated on the development of novel antigen receptors for T-cells with optimized specificity and efficacy in treating cancers.
Areas of Expertise
Information for Patients
Learn more about our clinical trials and the highly specialized care teams that lead them.
Immune Rejection Mechanisms in Melanoma, Renal Cancer and Other Human Cancers
Our laboratory's major interest is in understanding the mechanisms of immune tumor rejection and then developing reagents to translate this understanding into clinical trials. In the last decade, it has been established that the immune system can cause the complete and durable rejection of certain metastatic cancers in some individuals. Our understanding of this process has been greatly enhanced by the discovery of several dozen tumor-associated antigens expressed by human melanoma, which can be recognized by tumor-reactive T cells. At this point, our major new challenges include:
- Understanding why human melanomas frequently contain tumor-reactive T cells in their tumor infiltrating lymphocytes (TIL) and why other human tumors appear not to
- Discovering why human renal cancers respond to immunotherapies very similarly to melanomas, even without containing tumor-reactive TIL
- Developing the reagents necessary to induce T-cell-mediated rejection of non-melanoma tumors based on principles learned from treating melanoma with T-cell adoptive transfer
Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes
Mutated RAS: Targeting the "Untargetable" With T Cells
A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers
Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3
Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study
James C. Yang, M.D.
Dr. Yang graduated from the Massachusetts Institute of Technology with a B.S. in biology. He then completed his M.D. and surgical internship and residency at the University of California, San Diego. In 1984, he came to the Surgery Branch, NCI, as a medical staff fellow. He subsequently became a senior staff fellow, then a senior investigator in 1987. He has been involved in studies of the immune response to tumor-associated antigens and has been a principal investigator of clinical trials in renal cell carcinoma and soft tissue sarcoma.
There are no open positions at this time. Check back again later, or take a look at CCR's Careers page.
Learn more about CCR research advances, new discoveries and more on our news section.